Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors

Bibliographic Data

ID15522819
AuthorsQianwei Shen (Università di Camerino), Yulin Deng (0009-0006-6005-0634, Beijing Institute of Technology), Roberto Ciccocioppo (0000-0003-3126-9240, Università di Camerino, corresponding author), Nazzareno Cannella (0000-0002-2891-8679, Università di Camerino)
Year2017
Volume8
Pages234-234
Publication date2017-11-13
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2017.00234
PMID29180970
OpenAlexW2767818129
LanguageEN
Citations received2
References cited61

Cocaine addiction is a widespread psychiatric condition still waiting for approved efficacious medications. Previous studies suggested that simultaneous activation of nociceptin opioid (NOP) and mu opioid (MOP) receptors could be a successful strategy to treat cocaine addiction, but the paucity of molecules co-activating both receptors with comparable potency has hampered this line of research. Cebranopadol is a non-selective opioid agonist that at nanomolar concentration activates both NOP and MOP receptors and that recently reached phase-III clinical trials for cancer pain treatment. Here, we tested the effect of cebranopadol on cocaine self-administration (SA) in the rat. We found that under a fixed-ratio-5 schedule of reinforcement, cebranopadol (25 and 50 μg/kg) decreased cocaine but not saccharin SA, indicating a specific inhibition of psychostimulant consumption. In addition, cebranopadol (50 μg/kg) decreased the motivation for cocaine as detected by reduction of the break point measured in a progressive-ratio paradigm. Next, we found that cebranopadol retains its effect on cocaine consumption throughout a 7-day chronic treatment, suggesting a lack of tolerance development toward its effect. Finally, we found that only simultaneous blockade of NOP and MOP receptors by concomitant administration of the NOP antagonist SB-612111 (30 mg/kg) and naltrexone (2.5 mg/kg) reversed cebranopadol-induced decrease of cocaine SA, demonstrating that cebranopadol activates both NOP and classical opioid receptors to exert its effect. Our data, together with the fairly advanced clinical development of cebranopadol and its good tolerability profile in humans, indicate that cebranopadol is an appealing candidate for cocaine addiction treatment

Addiction · Agonist · Naltrexone · Nociceptin receptor · NOP · Opioid · Opioid peptide · Opioid receptor · Psychiatry · Receptor · Self-administration · μ-opioid receptor · Chemistry · Medicine · Neuropeptides and Animal Physiology · Pain Mechanisms and Treatments · Receptor Mechanisms and Signaling · Internal Medicine · Pharmacology

  • “This Isn’t the South Bronx”

    Maisam Alomar•Social Text•2020

  • NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference

    Open Access•Hongwu Li, Giulia Scuppa et al.•Frontiers in Psychiatry•2019

Unique citing works2
Citations per year0.29
Citation span2019 - 2020 (2)
Citation velocityhistorical
Highly citedNo
Citation typesNeutral: 2

Tools

Open DOISci-HubOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae